% | $
Quotes you view appear here for quick access.

iBio, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • mofisher22 mofisher22 Apr 18, 2012 7:09 PM Flag

    Whats your fav other than IBIO!

    gypsy and others, sorry for misstake on one of my pick, the symbol is NVIV, it is called invivo therepudics, check it out, tell me what you think, it is in category with ibio, in that highly spec, but in cutting edge tech that could become a blockbuster.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • gypsy, forgot to say, you might want to get back in psdv soon, getting ready for 3rd liftoff of the spring, hopefully the most successful

      • 1 Reply to mofisher22
      • CBLI - Cleveland BioLabs - Working on a drug to protect from radiation sickness. Hammered on April 4th when they lost BARDA funding. Biomedical Advanced Research and Development Authority of the Department of Health and Human Services (BARDA) is similar to DARPA only in the realm of medical research. Their compound CBLB502 can only have human testing for safety, side effects, and pharmacokinetics due to the ethics of exposing humans to radiation to test efficacy. The hitch is BARDA wants the FDA to judge the appropriateness of the animal models and their testing in those for efficacy. They stopped further funding until they do so. The drug inhibits a cell apoptosis (programmed cell death) pathway that is known to be activated by ionizing radiation. The drug would be of use in a radiologic or dirty bomb attack. Similar to iBIO in that they would use government funding to develop their initial drug candidate and bring it to market. The drug could then be studied for follow on indications such as chemotherapy related toxicities, to protect and preserve tissues that have suffered from lack of oxygen as a result of stokes, heart attacks, pulmonary embolisms, closed head traumas, ect.

        I also like Astex (ASTX) for the breadth and depth of their pipeline and their flush balance sheet. The are selling for less than their cash per share on their books. No need for dilution any time soon.

0.640.00(0.00%)Jul 22 4:00 PMEDT